HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

preempt

is a bacterial spray administered to newly hatched chicks that produces normal intestinal flora and decreases infection with Salmonella; contains 29 types of live bacteria
Also Known As:
CF-3 Salmonella spray
Networked: 79 relevant articles (6 outcomes, 23 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Aurora, Sheena K: 7 articles (09/2015 - 06/2010)
2. Turkel, Catherine C: 6 articles (09/2015 - 06/2010)
3. DeGryse, Ronald E: 5 articles (09/2015 - 06/2010)
4. Lipton, Richard B: 5 articles (09/2015 - 06/2010)
5. Silberstein, Stephen D: 5 articles (09/2015 - 06/2010)
6. Dodick, David W: 5 articles (09/2015 - 06/2010)
7. Diener, Hans-Christoph: 4 articles (09/2015 - 06/2010)
8. Turkel, C C: 4 articles (01/2014 - 07/2010)
9. Aurora, S K: 4 articles (01/2014 - 07/2010)
10. Dodick, D W: 4 articles (01/2014 - 07/2010)

Related Diseases

1. Migraine Disorders (Migraine)
2. Headache (Headaches)
01/01/2014 - "Our results support findings of PREEMPT study in a large cohort of patients, we believe, is representative of the patients seen in an average tertiary headache centre. "
04/16/2012 - "Pooled findings from two large phase III studies of virtually identical design (PREEMPT [Phase III REsearch Evaluating Migraine Prophylaxis Therapy] 1 and 2) showed that treatment with up to five cycles of onaBoNTA (155-195 units/cycle) at 12-week intervals was effective in reducing headache symptoms, decreasing headache-related disability, and improving health-related quality of life (HR-QOL) in patients with chronic migraine, approximately two-thirds of whom were overusing acute headache medications at baseline. "
03/30/2012 - "A pooled analysis of the data from two programmes of Phase 3 Research Evaluating Migraine Prophylaxis Therapy (PREEMPT 1 and 2) with BoNT-A in chronic migraine demonstrated significant benefit of BoNT-A over placebo with regard to the numbers of headache days and migraine episodes. "
09/01/2015 - "To help inform decisions about treating non-responders, we examined the probability of treatment cycle 1 non-responders responding in cycle 2, and cycle 1 and 2 non-responders responding in cycle 3. Pooled PREEMPT data (two studies: a 24-week, 2-cycle, double-blind, randomised (1:1), placebo-controlled, parallel-group phase, followed by a 32-week, 3-cycle, open-label phase) evaluated onabotulinumtoxinA (155-195 U) for prophylaxis of headaches in persons with CM (≥15 days/month with headache ≥4 h/day). "
01/01/2014 - "PREEMPT (two phase III studies: 24-week double-blind, placebo-controlled [DBPC], parallel-group phase, followed by 32-week open-label [OL] phase) evaluated the efficacy and safety of onabotulinumtoxinA in CM (≥15 days/month with headache lasting ≥4 h a day). "
3. Residual Neoplasm
4. Neoplasms (Cancer)
5. Pain (Aches)

Related Drugs and Biologics

1. onabotulinumtoxinA (Botox)
2. Botulinum Toxins (Botulinum Toxin)
3. Type A Botulinum Toxins (Botulinum A Toxin)
4. topiramate (Topamax)
5. Sufentanil (Sufenta)
6. Dietary Phosphorus
7. Proteins (Proteins, Gene)
8. Parathyroid Hormone (Parathormone)
9. Oxygen
10. Iron

Related Therapies and Procedures

1. Injections
2. Surgical Instruments (Clip)
3. Artificial Respiration (Mechanical Ventilation)
4. Laparotomy
5. Hysterectomy